Advances in emergent biological recognition elements and bioelectronics for diagnosing COVID-19

Praopim Limsakul\textsuperscript{1,2} · Krit Charupanit\textsuperscript{3} · Chochanon Moonla\textsuperscript{4} · Itthipon Jeerapan\textsuperscript{1,2}

Received: 4 January 2021 / Accepted: 26 January 2021 / Published online: 8 March 2021
© Qatar University and Springer Nature Switzerland AG 2021

Abstract
Coronaviruses pose a serious threat to public health. Tremendous efforts are dedicated to advance reliable and effective detection of coronaviruses. Currently, the coronavirus disease 2019 (COVID-19) diagnosis mainly relies on the detection of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) genetic materials by using reverse transcription-polymerase chain reaction (RT-PCR) assay. However, simpler and more rapid and reliable alternatives are needed to meet high demand during the pandemic. Biosensor-based diagnosis approaches become alternatives for selectively and rapidly detecting virus particles because of their biorecognition elements consisting of biomaterials that are specific to virus biomarkers. Here, we summarize biorecognition materials, including antibodies and antibody-like molecules, that are designed to recognize SARS-CoV-2 biomarkers and the advances of recently developed biosensors for COVID-19 diagnosis. The design of biorecognition materials or layers is crucial to maximize biosensing performances, such as high selectivity and sensitivity of virus detection. Additionally, the recent representative achievements in developing bioelectronics for sensing coronavirus are included. This review includes scholarly articles, mainly published in 2020 and early 2021. In addition to capturing the fast development in the fields of applied materials and biodiagnosis, the outlook of this rapidly evolving technology is summarized. Early diagnosis of COVID-19 could help prevent the spread of this contagious disease and provide significant information to medical teams to treat patients.

Keywords SARS-CoV-2 · COVID-19 · Biorecognition material · Antibody · Antibody-like molecule · Virus

1 Introduction
The coronavirus disease 2019 (COVID-19), which is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been a major global threat since late 2019. COVID-19 has been declared as a critical pandemic in 2020. As of early 2021, the report from www.worldometers.info/coronavirus/ shows that over 95,000,000 cases of COVID-19 have been confirmed around the world. 2,032,634 deaths were reported, attributable to SARS-CoV-2 infection (as of January 17, 2021) [1]. Reportedly, 40% to 45% of people infected with SARS-CoV-2 have no symptoms of COVID-19 [2–4]. This could allow the silent spread of the virus that causes uncontrolled transmission of SARS-CoV-2 throughout the globe [5]. Apart from asymptomatic patients, COVID-19 patients have a large variety of symptoms, leading to the difficulty to determine the infection [6]. Undoubtedly, researchers need to explore fast, accurate, and cost-effective approaches, such as biosensors, to detect viruses [7–9].

Early diagnosis of COVID-19 can help prevent the spread of this contagious disease. Thus, identifying viral biological markers (i.e., viral genetic material, viral proteins, or host immune responses to infection) and discovering their biorecognition molecules, which specifically bind to those markers, are important to enabling the development of a variety of methods for SARS-CoV-2 detections either in the laboratory setting or the point-of-care (POC) testing [10, 11]. The COVID-19 outbreak pushes the development of biosensors...
and bioelectronics forward, even more, to the advanced diagnosis technology for detecting viruses [12]. Although the nucleic acid amplification tests (NAATs), such as the real-time reverse transcription-polymerase chain reaction (RT-PCR), are recommended by the World Health Organization (WHO) as a standard approach to detect unique SARS-CoV-2 genome [13], this PCR-based method has some limitations; for example, the cost for instrumentation and operation limits the affordability. Rapid and accurate diagnosis is ideal for public strategic requirements to control the COVID-19 crisis [14, 15]. In addition, RT-PCR relies on special analysts and centralized laboratory in the hospital. Inevitably, this challenge stimulates researchers to develop new alternative strategies.

Advanced materials enable the design of high-performance biosensors and bioelectronics. For example, nanomaterials, such as graphene and gold nanoparticles, provide a large active surface-to-volume ratio, enhancing the efficient immobilization and conductivity. Utilizing advanced materials allows the development of nano/biosensors with high sensitivity and other preferable analytical performances for the detection of biochemicals in clinical applications, offering new alternatives to benchtop-based complex instruments [16–18]. Therefore, a broad range of advanced functional materials is applied to support the fabrication of SARS-CoV-2 sensing systems. A main group of the analyte indicating the presence of viruses is the genome (target). The preconcentration of targets is almost always mandatory in order to achieve the limit of detection of the developed protocols. An example of favored strategies is using genome amplification [19, 20]. Apart from the genome target, protein-based biomarkers are also important targets used to indicate SARS-CoV-2 infection. Compared with targeting genetic materials from viruses, the main limitation of detecting non-genetic targets (such as proteins or antibodies) is an extremely low concentration. Some analytical challenges here are considered. Challenges are peculiar to trace bioanalysis when dealing with low concentrations of targets and small volumes of samples. If we can detect viral biomarkers at the early stage of SARS-CoV-2 infection, which usually presents in ultralow concentrations of viral targets, by using fast and reliable approaches, it is essential to strengthening the way to slow down the spreading of viruses or, importantly, save the life of the patient effectively.

In this review, we aim to describe the current advances of biosensor platforms for COVID-19 diagnosis (Fig. 1). Only articles written in English are considered. In addition to several published review articles [21, 22], we expand our discussion focusing on biological recognition elements and bioelectronics. Starting with the basic biological structure and cell entry mechanism of SARS-CoV-2, we summarize the possible antigens and biomarkers, such as viral ribonucleic acid (RNA) and proteins, or human immune response to the infection, which can be used to identify the presence of SARS-CoV-2 in humans. Subsequently, we introduce the biorecognition elements, such as nucleic acid probes, antibodies, and antibody-like molecules, that have been applied to specifically bind to those viral antigens and biomarkers. Although antibodies are primarily used for the detection of viral proteins, there is the possibility of using antibody-like molecules. The advantages of antibody-like molecules over antibodies are described. Moreover, we demonstrate the current advancement of using bio-recognition elements for diagnosis of COVID-19 from patient samples. Lastly, we show recent examples of the integration between viral biomarkers and the advent of bio-recognition elements in biosensors based on electrochemical bioelectronics to rapidly detect SARS-CoV-2 in patient samples.

2 The structure of SARS-CoV-2 and entering mechanism

Understanding the pathogenesis of SARS-CoV-2 could lead to appropriate diagnosis and therapeutics. The novel coronavirus, SARS-CoV-2, is closely related to betacoronavirus [23, 24] that had caused two outbreaks at the beginning of the twenty-first century, e.g., severe acute respiratory syndrome (SARS) caused by SARS-CoV in 2002 [25, 26] and Middle East respiratory syndrome (MERS) caused by MERS-CoV in 2012 [27, 28]. Similar to other coronaviruses, SARS-CoV-2, which is a positive-sense single-stranded RNA (+ssRNA) virus, shares ~80% and 50% genome sequence identity with SARS-CoV and MERS-CoV, respectively, and its genome consists of ~30,000 base pairs (bp) in length encoding four main structural proteins, e.g., spike (S), nucleocapsid (N), membrane (M), envelope (E), nonstructural proteins, and accessory proteins (as shown in Fig. 2a) [29–32]. Among these proteins, the sequence of the SARS-CoV-2 S protein is more diverse with about 77% identity to SARS-CoV, while other proteins are highly evolutionary conserved [33]. Therefore, distinct domains within the S protein are used by different coronaviruses to recognize a variety of attachments and entry receptors [34].

The engagement between the SARS-CoV-2 S protein and a host cell receptor initiates virus entering the host cell. The SARS-CoV-2 S protein consists of 1273 amino acids (Fig. 2b), including a signal peptide (residues 1–13), an N-terminal subunit (S1; residues 14–685) that mediates receptor binding, and a C-terminal subunit (S2; residues 686–1273) that mediates fusion between virus and the membrane of the host cell [31, 35] [36]. For viral attachment to the surface of host cells, the receptor-binding domain (RBD; residues 319–541) of the S1 subunit binds to the host angiotensin-converting enzyme 2 (ACE2) receptor with high affinity (dissociation constant, \(K_d = 14.7 \text{ nM} \)) [37]). For viral entry, with facilitating of the host protease, e.g., transmembrane serine protease 2 (TMPRSS2) on the surface of host cells for the S protein priming, it cleaves the boundary between S1 and S2 that triggers a conformational change in the S2 subunit and allows the fusion peptide (residues 788–806) of the S2 subunit to fuse to the host cells, resulting in the release of...
the viral genome into the host cells [38, 39]. The SARS-CoV-2 genetic materials then utilize the molecular machinery of the host cell to replicate themselves and release the new virus particles into the host organism. Understanding the structure and function of SARS-CoV-2 allows researchers to design the effective approaches for reliable and rapid diagnosis of COVID-19 and to develop the potential treatments to meet the high demand during the pandemic.

**3 SARS-CoV-2 biomarkers and biorecognition elements**

Several viral antigens and biomarkers are identified to be used as an indicator for SARS-CoV-2 infection [40]. Generally, the amount of SARS-CoV-2 presenting in patients depends on the window period and different types of patient samples, including nasopharyngeal swabs, sputum, urine, or stool. The mean

![Fig. 1](image1.png)

**Fig. 1** Illustrations of the SARS-CoV-2 and the concept of using biosensing technologies for effective COVID-19 diagnosis, including a sampling, b coronavirus structure, c biodiagnostic tools, and d modern clinical systems, which seeks to deliver important data and allows fast and efficient managements of the individual and public health.

![Fig. 2](image2.png)

**Fig. 2** The structure and cell entry mechanism of SARS-CoV-2. a Four structural proteins of SARS-CoV-2 include spike (S), nucleocapsid (N), membrane (M), and envelope (E) proteins. To enter host cells, the SARS-CoV-2 S protein binds to host angiotensin-converting enzyme 2 (ACE2) receptors (shown in red). Subsequently, the surface protease, e.g., transmembrane protease serine 2 (TMPRSS2, shown in purple), cleaves at the S1/S2 boundary which triggers a series of conformational changes that lead to fusion between the viral envelope and the target host cell membrane. b Schematic of the SARS-CoV-2 S protein. The total length is 1273 amino acids which consist of a signal peptide (residue: 1–13) located at the N-terminus, the S1 subunit (residue: 14–685, shown in yellow), and the S2 subunit (residue: 686–1273, shown in green). In the S1 subunit, there are an N-terminal domain (residue: 14–305) and a receptor-binding domain (RBD; residue: 319–541, highlighted in orange). In the S2 subunit, there are the fusion peptide (FP; residue: 788–806), heptapeptide repeat sequence 1 and 2 (residue: 912–984 for HR1, and 1163–1213 for HR2), transmembrane domain (TM; residue: 1213–1237), and cytoplasm domain (residue: 1237–1273). Using the RBD, the trimeric spike molecule binds to ACE2.
incubation period for COVID-19 is typically 5–6 days, and the infectiousness could start about 11–12 days before symptom onset and peaked at onset [41–43]. To diagnose COVID-19, several samples from patients are collected to extract the viral genetic materials which are later determined by RT-PCR. Particularly, the viral loads in nasopharyngeal swabs and sputum samples reached the maximum level at around 5–6 days after symptom onset (~10^4 to 10^7 copies mL^-1) [44]. Currently, the molecular diagnostics is the key methods that have been applied to detect viral biological markers, including viral genetic material (i.e., RNA) or viral proteins (i.e., S or N proteins) in patient samples [45]. The viral genetic material is typically targeted because it can be amplified to enhance the detection sensitivity. Conversely, viral proteins are difficult for direct detection because of their trace amount [46]. In addition to viral biological markers, the host responses to infection are another indicator for COVID-19 prognosis [47]. Thus, detecting viral RNA, proteins, or human immunoglobulins with biorecognition elements (e.g., antibodies, antibody-like molecules, and nucleic acid probes) that specifically bind to those biomarkers enables the possibility to develop a variety of methods for SARS-CoV-2 detection [16]. The viral biomarkers with their recognition molecules are discussed in the following section.

For the SARS-CoV-2 RNA, it is currently used as a major biomarker for COVID-19 diagnosis, and its standard recognition molecule is nucleic acid probes. Due to the advent of next-generation sequencing (NGS) and bioinformatics, the whole genome of SARS-CoV-2 has been identified that enables the design of the SARS-CoV-2-specific primers (short nucleic acid sequence) to amplify a unique sequence of SARS-CoV-2 genome using RT-PCR [31]. The common targets of the SARS-CoV-2 genome include the genes encoding the E, N, and S proteins, the open reading frame 1ab, and the RNA-dependent RNA polymerase (RdRP) gene, of which each of them differently affects the specificity of RT-PCR [46, 48]. For example, the S gene and RdRP gene are commonly used to differentiate SARS-CoV-2 from other coronaviruses, while the E and N genes are used to identify coronaviruses because these genes are more conserved among coronaviruses that may have cross-reaction [31, 44]. Consequently, the whole-genome sequences of SARS-CoV-2 allow researchers to design specific probes to target and amplify viral genetic material in the RT-PCR process.

For the SARS-CoV-2 proteins, the N and S proteins are typically used as the antigens or biomarkers for viral detection, and their biorecognition molecules can be either antibodies or antibody-like molecules. The N protein, which is a multifunction RNA-binding protein involved in viral RNA replication and assembly, expresses in high levels in infected cells at the early stage of SARS-CoV-2 infection [49]. Moreover, the S protein, which is a large type-I transmembrane glycoprotein covering the surface of SARS-CoV-2, binds to host ACE2 to facilitate the viral entry into target cells [35, 50]. Targeting either N or S protein by biorecognition molecules could be useful to developing diagnostic systems. For example, monoclonal antibodies (mAbs, Fig. 3a) have been mainly used to recognize antigens, and other antibody-like molecules (see Fig. 3b–f), such as antigen-binding fragment (Fab), single-chain variable fragment (scFv), single-domain antibody (nanobody), and monobody, can also bind to antigens. The binding specificity and affinity between antibodies or antibody-like molecules and target antigens can be improved through protein engineering techniques which consist of the following steps (Fig. 3g). Firstly, the library containing a diversity of variants is generated. In this step, the library of mAbs is isolated from B-cell samples of virus-infected patients, or the synthetic library of biorecognition molecules is diversified by mutagenesis. Secondly, these libraries are screened/selected against the target molecule through the display technology, especially the phage display that is widely used for in vitro selection [56]. Lastly, the function of selected variants is verified by a double-antibody sandwich enzyme-linked immunosorbent assay (ELISA) or affinity determination, before use. Thus, utilizing protein engineering techniques, the binding affinity of biorecognition molecules can be improved with high specificity against the viral markers. The examples of improving the binding of biorecognition molecules (antibody and antibody-like molecule) against viral proteins (e.g., N or S protein) are described in the following paragraph.

Recently, several mAbs and antibody-like molecules have been produced to specifically target SARS-CoV-2 protein markers or antigens (Table 1). For instance, the anti-SARS-CoV-2 antibody library derived from peripheral blood samples of COVID-19 patients was generated by phage display technology and screened against the SARS-CoV-2 N protein. This led to JSo8 antibody with high binding affinity that can neutralize antibody (nAb). For instance, nAb for SARS-CoV, such as CR3022, also has potential cross-neutralizing activity against SARS-CoV-2 infection due to the sequence identity of the S protein (77%) between SARS-CoV and SARS-CoV-2 [33, 61]. Despite of using an individual viral antigen, anti-SARS-CoV-2 antibodies can be selected using recombinant...
antigens, such as N, S, RBD, or ectodomain of the S protein [66, 67].

In addition to mAb, antibody-like molecules, such as nanobody (derived from camelid single-chain antibodies (VHH)) and monobody (derived from human fibronectin domain III), are an alternative binding protein against viral proteins because of their smaller size, being easier to be produced (in yeast or bacteria), and better binding affinity ($K_D$ in the range of pM–nM) than those of mAbs [68]. For example, a yeast surface-display library of synthetic nanobody sequences was constructed and screened against a mutant form of the SARS-CoV-2 S protein [39]. After several rounds of selection and optimization, a trivalent form of Nb6 binds to the S protein with femtomolar affinity. Another example of nanobody library is that it can be constructed from a llama immunized with the recombinant RBD, and this library was selected using a proteomic strategy to achieve anti-RBD nanobodies with picomolar to femtomolar affinity [62]. Apart from the nanobody, the monobody library can be synthetically constructed and screened against the SARS-CoV-2 S1 subunit, resulting in anti-S1 monobodies with sub-nanomolar to nanomolar affinity [63]. These monobodies were then applied...
to capture SARS-CoV-2 particles from the nasal swab samples of patients. Representative of biorecognition molecules designed to target SARS-CoV-2 antigens are summarized in Table 1.

For the host immune responses to SARS-CoV-2 infection, immunoglobulin M (IgM) and IgG provide a defense mechanism, and they can be used as another indicator of SARS-CoV-2 infection for the serology test [47]. During viral infections, IgM is the first antibody to be produced by the immune system that can be detected in the first week after infection and reached its peak after 2 weeks before reduced to near-background level. IgG, on the other hand, is produced after 1 week of infection, reached its peak in 3 weeks, and remained at a high level for long-term immunity and immunological memory [69–71]. In other words, the detection of IgM antibodies could indicate recent exposure to SARS-CoV-2, while the detection of IgG antibodies could indicate virus exposure some time ago. Hence, the SARS-CoV-2 antigens are generally used to target IgM or IgG. Chemiluminescence immunoassay (CLIA) is an example that utilizes the magnetic beads coated with SARS-CoV-2 antigens (e.g., N and S proteins) to detect IgM or IgG in serum, and the amount of detected IgM or IgG is quantified by the CLIA analyzer [72]. However, the sequential production of IgM and IgG in COVID-19 patients is still inconclusive because their production can be time-dependent in different patients which raises diagnostic problems [73]. Recently, immunoglobulin A (IgA) antibodies have been found to be a promising biomarker for the detection of early SARS-CoV-2-specific humoral responses as it can be frequently detected before the presence of IgG [73, 74].

### 4 Recent biosensing approaches for detecting SARS-CoV-2

In the present, the COVID-19 diagnosis mainly relies on the detection of SARS-CoV-2 RNA by real-time RT-PCR assay. Several test kits based on RT-PCR have been developed and commercially available to target various SARS-CoV-2 genes with relatively high sensitivity [46, 75, 76]. However, these test kits still suffer from limitations, including long turnaround times, complicated operation, expensive equipment, and high false-negative rate [47, 48, 77]. Therefore, the simple and cost-effective diagnostic methods are needed to accurately and rapidly screen patients during the pandemic. In this section, we summarize the recently developed molecular diagnostic methods that use different virus biological markers as a target, such as viral RNA, proteins, or human IgM/IgG.

#### Table 1 Representative biorecognition molecules targeting SARS-CoV-2

| Name | Source | Recognition molecule | Target | Dissociation constant |
|------|--------|----------------------|--------|-----------------------|
| JS01-16 mAb (16 mAbs) [57] | Blood samples from five COVID-19 patients | Fab and mAb | N protein of SARS-CoV-2 | 0.069 to 16 nM |
| P2B-2F6 mAb, and P2 clones mAbs [58] | Blood samples from eight COVID-19 patients | mAb | RBD of SARS-CoV-2 | 5.14 nM, 1.38 to 21.29 nM |
| MD17, MD29, MD45, MD47, MD62, MD63, MD65, MD67 [59] | Blood samples from COVID-19 convalescence or from patients with severe ongoing disease | scFv (mAb in a scFv-Fc format) | RBD of SARS-CoV-2 | 0.4 to 5.8 nM |
| 47D11 [60] | Hydriobium culture supernatants of H2L2 mouse immunized with the purified S protein (ectodomain) or RBD of SARS-CoV or CoV-2 | mAb (with human IgG1 backbone) | S protein (ectodomain) and RBD of SARS-CoV and SARS-CoV-2 | 0.745 and 16.1 nM (S and RBD of SARS-CoV) |
| 47D11 [60] | | | | 10.8 and 9.6 nM (S and RBD of SARS-CoV-2) |
| 80R [50] | B cells of 57 unimmunized donors | scFv, mAb (with human IgG1 backbone) | S1 subunit of SARS-CoV S protein | 32.3 nM, 1.59 nM |
| CR3022 [61] | Lymphocytes of a convalescent SARS patient | scFv, mAb (with human IgG1 backbone) | RBD of SARS-CoV-2 | 6.28 nM |
| mNb6 [39] | Synthetic nanobody | Nanobody | S protein (ectodomain) of SARS-CoV-2 | 0.45 nM |
| Nb20, Nb21 [62] | Blood from Llama immunized with an RBD-Fc fusion protein | Vh/H antibodies or nanobody | RBD of SARS-CoV2 | Nb20: 10.4 pM, Nb21:< 1 pM |
| Spike-binding monobody clones 4, 6b, and 12b [63] | Synthetic monobody | Monobody | S1 subunit of SARS-CoV-2 S protein | 4: 1.94 nM; 6b: 0.76 nM; 12b: 0.62 nM |
colorimetry, fluorimetry, and turbidity. Besides DNA amplification, reverse transcription LAMP (RT-LAMP) is used for amplifying specific RNA sequences that allow the direct detection of viral RNA [79]. Furthermore, combining LAMP or RT-LAMP with CRISPR, the DNA-endonuclease-targeted-CRISPR-trans-reporter (DETECTR) can further increase the specificity during amplification (Fig. 4a) [81]. The SARS-CoV-2 DETECTR assay provides a visualization of the result and fast (<40 min) detection of SARS-CoV-2 from a patient sample with 95% sensitivity and 100% specificity [80].

For detecting viral proteins and human immunoglobulins, the detection of these proteins provides an alternative diagnosis for COVID-19. One of the assays that have been applied to detect viral proteins is ELISA. In this assay, the specific binding between antibody and viral proteins (immobilized on a surface of a plate) can be detected with another additional tracer antibody that produces a colorimetric or fluorescent-based readout [82]. Thus, antibodies are important for targeting virus in this assay. Similarly, antibody-like molecules which recognize viral proteins can be used as an alternative to antibodies. For example, the recently engineered monobodies, which specifically bind to the S1 subunit of SARS-CoV-2, were used in ELISA assay, and the result was comparable as using antibody (Fig. 4b) [63]. These monobodies can also be coated on the magnetic beads to pull down and enrich SARS-CoV-2 virus particles from patient nasal swab samples for RT-PCR. In addition, human immunoglobulins, e.g., IgG or IgM can be quantitatively detected by a multiplex label-free antigen microarray on the Arrayed Imaging Reflectometry (AIR) platform [83].

Another approach to detect viral proteins is biosensors of which recognition domains are generally made of antibodies recognizing viral antigens, but transduction systems can be different. For instance, a nanoplasmonic resonance sensor utilizes the immobilized SARS-CoV-2 mAbs to detect SARS-CoV-2 virus particles in one step (<15 min) with the virus range of 0 to 10⁷ vp mL⁻¹ [84]. In addition to detecting virus particles, an opto-microfluidic sensing platform, of which sensing unit is based on localized surface plasmon resonance, was developed to rapidly detect antibodies specific to the SARS-CoV-2 S protein in human plasma (<30 min) with the limit of detection of ~0.08 ng mL⁻¹ [85]. Additionally, engineering the surface of quartz crystals can form a sensitive transducer to detect biotargets [86, 87]. This concept can be integrated with a quartz crystal microbalance for sensing SARS-CoV-2 [88]. For instance, the S1 protein bears hydrophobic and positive charged surfaces. Therefore, it can interact with hydrophobic ends and carboxylated moieties which can be attached on the quartz crystal microbalance. This binding event causes the change of mass of the microbalance, thus providing sensitive analytical signals. However, nonspecific adsorption is challenging. Anti-S protein (as a bioreceptor) is a candidate to be functionalized on the quartz crystal surface to ensure high specificity to SARS-CoV-2. Moreover, electrochemical biosensors whose biorecognition element was made of membrane-engineered mammalian cells bearing the human chimeric spike S1 antibody can detect the SARS-CoV-2 S1 subunit of S protein (~3 min) with a detection limit of 1 fg mL⁻¹ [89]. Similarly, a field-effect transistor (FET)-based biosensor utilizes immobilized SARS-CoV-2 mAbs on a graphene sheet to detect SARS-CoV-2 S proteins at concentrations of 1 fg mL⁻¹ in phosphate-buffered saline and 100 fg mL⁻¹ in clinical transport medium [90]. More detail of the bio-FET and its application will be elaborated in Sect. 5. Since similarity between coronaviruses, simultaneously detecting multiple SARS-CoV-2 biomarkers, could provide rapid and low-cost COVID-19 diagnosis. The SARS-CoV-2 RapidPlex is a graphene-based multiplexed telemedicine platform to detect SARS-CoV-2 N protein, inflammatory biomarker C-reactive protein (CRP), and specific immunoglobulins against SARS-CoV-2 S1 protein by coating specific anti-N protein mAbs, anti-CRP mAbs, and purified SARS-CoV-2 S1 proteins, respectively (detection time can be as low as 1 min, see Fig. 5a). Different expression levels of these antigens can be used to track the infection progression the COVID-19 (Table 2). The details of the bioelectrode designs and electrochemical detection systems will be discussed further in the following section.

5 Emerging electrochemical bioelectronics toward COVID-19 diagnosis

POC biosensors offers rapid and on-site detection of viruses and infection risks [95, 96]. Two key features need to be considered for POC biosensors, including portability and sensitivity. Portable sensing devices open unique opportunities to speedily on-site detect viruses or track relevant symptoms by analyzing body fluids (such as saliva and blood) or viruses spread in our surroundings [95, 97]. Besides, bioelectronics are crucial to strengthening modern digital health initiatives, enabling the immediate management because they are ready to provide measurable electrical signals that are convenient to connect to digital systems [98–100]. Electrochemical detection approaches, for example, are extensively applied to POC applications. In the case of virus detection, electrochemical sensors can be designed to analyze viral protein-based biomarkers, apart from detection of viral genetic material. However, unlike genome materials which can be amplified, it is needed to engineer the sensor to provide a very sensitive and low limit of detection for detecting protein-based biomarkers.

Expanding from the previous discussion about viral biomarkers and biorecognition elements in Sects. 3 and 4, the basis of many electrochemical immunosensors relies on the specific virus-antibody recognition. The binding interaction
between the immobilized capturing molecule (i.e., antibody) as a bioreceptor on the solid supports (i.e., electrode) and the target virus (or the relevant biocomponent from the virus) can form a stable complex. This recognition event can be designed to cause electrochemical changes. This event is detectable by using an electrical transducer. In terms of electrical transducing parameters, the interaction occurring on the sensing electrode can be converted into four main characteristic responses, depending on the detection methods, including potentiometric (i.e., the potential change of an indicator electrode) [101], voltammetric/amperometric (i.e., the associated current as a function of potential) [102, 103], conductometric (i.e., the conductivity or resistance) [104], and impedimetric (i.e., the impedance of a system) signals with respect to the target analyte concentrations [105]. Moreover, this can be extended to a microelectronic-based transducer, such as a FET-based biosensor. The binding of viruses or their antigens can induce the change in the surface potential of the device. This event causes the change in conductance of the FET channel, allowing the measurable signal to indicate the presence of viruses [90, 106].

A recent example of electrochemical sensors for rapid COVID-19 diagnosis is shown in Fig. 5a [91].
design relies on sandwich- and indirect-based immunosensing mechanisms. The SARS-CoV-2 N protein, specific immunoglobulins against the SARS-CoV-2 S protein (S1) (S1-IgM and S1-IgG), and CRP are biomarkers used to...
The presence of virus biomarkers to track the infection progression of the COVID-19 disease stage using SARS-CoV-2 sensors. Adapted with permission from [91]. Copyright 2020, Elsevier

| Viral antigen | IgM | IgG | CRP | Expected outcome |
|---------------|-----|-----|-----|-----------------|
| –             | –   | –   | –   | Healthy         |
| +             | +   | –   | –   | Infectious, presymptomatic |
| +             | +   | +   | –   | Infectious, asymptomatic |
| +             | +   | +   | +   | Infectious, symptomatic |
| –             | +   | +   | –   | Recovered (recently) |
| –             | –   | +   | –   | Recovered (long term) |
| –             | –   | –   | +   | Inflammation/infection not due to COVID-19 |

+, higher than threshold; –, lower than threshold; ||, or
approach used for the bioreceptor immobilization is one of the significant aspects in offering a successful affinity-based bioelectrode.

Another example of electrochemical sensor for SARS-CoV-2 relies on supersandwich-type biorecognition, as shown in Fig. 5b [92]. This biosensor was designed to detect RNA present in SARS-CoV-2. In this example, graphene oxide is functionalized with macrocyclic oligomer calixarene, i.e., p-sulfocalix[8]arene (SCX8). The resulting calixarene/carbon composite is also attached with gold and toluidine blue materials to provide a high electrochemical signal. With the presence of the target RNA from the virus, the RNA target can bind specifically with the capture probe which is attached on the gold/Fe3O4 nanoparticles via gold and thiol on the capture probe. Note that Fe3O4 nanoparticles are designed to allow magnetic separation [118]. Sequentially, the resulting target-capture probe combination binds with SCX8 attached on gold/toluidine blue/graphene composite (Au@SCX8-RGO-toluidine blue nanocomposites). Host-guest recognition between p-sulfocalix[8]arene and toluidine blue is chosen to ensure reliable and clear electrical signal [122]. Labeled signal probe and auxiliary probe are also used to bind with Au@SCX8-RGO-toluidine blue nanocomposites. The 5'- and 3'-ends of target sequence are matching to the capture probe and the label probe, respectively. The auxiliary probe is designed to give a lengthy shape by binding with the label probe areas. Therefore, the sandwich configuration consists of (1) the capture probe, (2) RNA target in the middle of sandwich, and (3) the labeled signal probe. Hence, with the presence of the target (even 10−12 M), the distinct differential pulse voltammetric peak related to the electrochemical toluidine blue redox probe can be observed. The amplifying signal strategy by combining the label probe with toluidine blue and other materials suggests a way to address the common challenge pertaining to low analytical signal. The clear peak current can be measured as an analytical signal. This approach is highly sensitive that no extra steps (e.g., nucleic acid amplification or reverse transcription) are required. In addition, the toluidine blue signal can be read by a smartphone.

A transistor that employs an electric field to regulate the flow of current can be modified to fabricate a sensitive biosensor [123]. An example of a FET-based biosensor for monitoring SARS-CoV-2 was demonstrated as shown in Fig. 5c [90, 93]. Graphene-based material is used to immobilize the SARS-CoV-2 spike antibody by using 1-pyrenebutyric acid N-hydroxysuccinimide ester as a linker. This immobilized coronavirus spike antibody is a recognition on the drainage surface. Upon the addition of the target, real-time responses with a wide dynamic range can be obtained. When testing the developed biosensor with MERS-CoV S proteins, the signal is absent. This test of immobilized antibody against the other viruses on the graphene-based transistor proves the high specificity to the target (i.e., SARS-CoV-2 antigen).

Another representative is based on a label-free paper-based electrochemical device, as shown in Fig. 5d [94]. The mechanism for the detection of the SARS-CoV-2 antibody relies on the binding event of the antibody target with the SARS-CoV-2 S protein receptor-binding domain (RBD), which is attached on the detection zone of the graphene-based electrode sensor. The immobilization of the RBD is obtained by using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide/N-hydroxy succinimide (EDC/NHS) coupling on the carboxylated graphene surface. Upon the addition of antibodies existing in the serum sample, the target will bind with the biorecognition layer. This event causes the blockage of electrochemically active surface. Therefore, when scanning square-wave voltammetry in the redox probe solution (i.e., [Fe(CN)6]3−/4−), the signal of the redox probe is turned off, indicating the presence of SARS-CoV-2 IgG or and SARS-CoV-2 IgM. This hindering process is sensitive as the system can monitor the target with the detection limit of ~0.1 ng mL−1 immunoglobulins (IgG and IgM). The same concept is also extended for the detection of viral antigen. The paper-based sensor was designed for sensing SARS-CoV-2 S protein. In this case, SARS-CoV-2 IgM was used to be immobilized on the detection area. The result shows that the electrochemical sensor for monitoring the SARS-CoV-2 RBD provides a dynamic range of 1–1000 ng mL−1 with a detection limit of 0.11 ng mL−1. Even though the detection limit of this sensor is low, the target in the sample obtained from nasopharyngeal swab is as low as picograms per milliliter. Therefore, further improvement is still required.

### 6 Conclusions and prospects

The COVID-19 pandemic is an ongoing critical global challenge since December 2019. The battle against COVID-19 requires efforts to deal with public health management. Although “social distancing” is important to flatten the curve of COVID-19 spreading, society, and economy cannot be completely stopped. Therefore, developing materials and systems to support effective COVID-19 detection is vital. Such requirements challenge multidisciplinary researchers to develop simple, high-throughput, and accurate diagnostic tools.

Tremendous progress has been made to develop diagnosis assay/kits that can accurately and rapidly detect viral biomarkers especially in asymptomatic and/or early-stage patients for reducing the spread of this disease. RT-PCR typically serves as a routine method for the detection of SARS-CoV-2 genetic material; however, it is costly, time consuming, labor intensive, and requires specialized laboratory equipment. Biosensors, on the other hand, provide low-cost, rapid, and sensitive detection of SARS-CoV-2 virus particles [124, 125]. General platforms of biosensors for SARS-CoV-2 detection involve three important components, including (1) the target biomarkers of virus (e.g., viral RNA, viral proteins, or human
immunoglobulins), (2) identification methods (based on biorecognition materials, e.g., antibodies, antibody-like molecules, or nucleic acid probes), and (3) the transduction systems for signal amplification (based on electrical, electrochemical, optical, surface plasmon resonance, and fluorescent signals) [45]. Using RNA as a target can be inconvenient because it requires the additional RNA extraction step from patient sample. Using viral protein as a target, on the other hand, allows direct detection in patient sample. Importantly, the binding affinity between biorecognition molecules and their target viral proteins needs to be improved to increase specificity of biosensor to target SARS-CoV-2. The mAbs are usually used as the biorecognition molecules in many detection assays and biosensors because they are highly specific to the target antigen. However, mAbs are complex molecules with 150 kDa that leads to high manufacturing cost and difficult production process. Alternatively, antibody-like molecules are small and easy to produce (in bacteria or yeast). With the advent of protein engineering techniques (e.g., rational design and directed evolution), these molecules can be engineered to be highly specific to target biomarkers. Therefore, antibody-like molecules could be a promising alternative bioreognition unit to mAbs for the detection of viral proteins.

Many diagnosis assays/kits for the detection of SARS-CoV-2 have been approved under Emergency Use Authorization (EUA) by The United States Food and Drug Administration (FDA) to be commercialized since 2020. These in vitro diagnostic kits are used to detect different SARS-CoV-2 biomarkers, such as the Xpert Xpress SARS-CoV-2 (Cepheid) and cobas SARS-CoV-2 kits (Roche Molecular Systems, Inc) to detect viral nucleic acids by RT-PCR, BD Veritor System for Rapid Detection of SARS-CoV-2 (Becton, Dickinson and Company) and BinaxNOW COVID-19 Ag Card (Abbott Diagnostics Scarborough, Inc.) to detect the N protein in nasal swabs, Assure COVID-19 IgG/IgM Rapid Test Device (Assure Tech. (Hangzhou) Co., Ltd.) and RightSign COVID-19 IgG/IgM Rapid Test Cassette (Hangzhou Biotest Biotech Co., Ltd.) to detect IgM and IgG antibodies specific to SARS-CoV-2 in human venous whole blood sample and fingerstick whole blood. More examples of in vitro diagnostic kits for COVID-19 can be found on the FDA website. https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/vitro-diagnostics-euas [76].

This review also includes examples of coronavirus detection using electrochemical approaches. Electrochemical sensing strategies represent attractive POC testing alternatives. Apart from conventional gold-standard methods which have limitations for speedy on-site diagnosis, it is crucial to develop the sensing device that enables the rapid assessment and promotes the telemedicine testing for field applications. In this regard, the development of a wireless telemedicine sensing platform offers fast communications of the identified real-time patient’s infection information/status delivered to the medical care system via mobile health platforms, regardless of the location. The state of the art in such bioelectronics and wireless technologies thus may fill the need for widespread COVID-19 testing and surpasses the testing backlogs. Although the non-invasive detection of the sensing platform in human saliva sample is safe and user-friendly for at-home use, the validation of the relationship between saliva and serum concentrations over the course of the SARS-CoV-2 infection is still required to achieve an accurate assay. There still remain much to be done as accurate measurements at a trace level of targets are required and crucial.

The requirement to obtain simple and rapid analysis while using small sample volumes draws attention to electrochemical sensors. We describe some representatives of recent technology to detect coronavirus. Nanomaterials are powerful to support the fabrication of electrodes and allow reliable immobilization of biorecognition layers on the electrode surface. Functional materials are also essential to enhance analytical performances, such as high signal-to-noise ratio, sensitivity, and stability. Integrated electrode arrays provide multiplex detection of multicomponents (targets) which indicates the COVID-19 disease in patients. Moreover, the integration of other technologies, such as microfluidic-integrated systems and microelectronics, can enable the high-throughput and fully automated sampling-handling detection and telemedicine fashion. With the achievements in developing bioelectronics, it is expected that the obtained diagnostic tools through smart micro total analysis systems will not only support the acquisition of signals indicating the presence of viral targets, but also data processing, storage, and the extraction of specific features. The important data will then be sent out to the central government or public healthcare organization to regulate the pandemic.

Funding I.J. was supported by the Faculty of Science Research Fund 2021 (contract number: 264003), Prince of Songkla University, Hat Yai, Thailand.

Declarations

Conflict of interest The authors declare that they have no conflict of interest.

References

1. COVID-19 Coronavirus Pandemic. 2021 [cited Access January 18, 2021]; Available from: https://www.worldometers.info/coronavirus/
2. D.P. Oran, E.J. Topol, Prevalence of Asymptomatic SARS-CoV-2 infection. Ann. Intern. Med. 173, 362–367 (2020). https://doi.org/10.7326/M20-3012
30. S. Jiang, C. Hillyer, L. Du, Neutralizing antibodies against SARS-CoV-2 and other human coronaviruses. *Trends Immunol.* **41**, 355–359 (2020). https://doi.org/10.1016/j.ti.2020.03.007

31. P. Zhou, X.-L. Yang, X.-G. Wang, B. Hu, L. Zhang, W. Zhang, H.-R. Si, Y. Zhu, B. Li, C.-L. Huang, H.-D. Chen, J. Chen, Y. Luo, H. Guo, R.-D. Jiang, M.-Q. Liu, Y. Chen, X.-R. Shen, X. Wang, X.-S. Zheng, K. Zhao, Q.-J. Chen, F. Deng, L.-L. Liu, B. Yan, F.-X. Zhan, Y.-Y. Wang, G.-F. Xiao, Z.-L. Shi, A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature* **579**, 270–273 (2020). https://doi.org/10.1038/s41586-020-2012-7

32. R. Lu, X. Zhao, J. Li, P. Niu, B. Yang, H. Wu, W. Wang, H. Song, B. Huang, N. Zhu, Y. Bi, X. Ma, F. Zhan, L. Wang, T. Hu, H. Zhou, Z. Hu, W. Zhou, L. Zhao, J. Chen, Y. Meng, J. Wang, Y. Lin, J. Yuan, Z. Xie, J. Ma, W.J. Liu, D. Wang, W. Xu, E.C. Holmes, G.F. Gao, G. Wu, W. Chen, W. Shi, T. Tan, Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origin and receptor binding. *Lancet* **395**, 565–574 (2020). https://doi.org/10.1016/S0140-6736(20)30251-8

33. Y. Zhou, Y. Hou, J. Shen, Y. Huang, W. Martin, F. Cheng, Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2. *Cell Discovery* **6**, 14 (2020). https://doi.org/10.1038/s41421-020-0153-3

34. A.C. Walls, Y.-J. Park, M.A. Tortorici, A. Wall, A.T. McGuire, D. Veesler, Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. *Cell* **181**, 281–292.e6 (2020). https://doi.org/10.1016/j.cell.2020.02.058

35. Y. Huang, C. Yang, X.-t. Xu, W. Xu, S.-w. Liu, Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19. *Acta Pharmacol. Sin.* **41**, 1141–1149 (2020). https://doi.org/10.1038/s41401-020-04854

36. J. Hao, A. Le Bas, R.R. Ruza, H.M.E. Duyvestein, H. Nikolajek, T. Malinowska, T.K. Tan, P. Rijal, M.W. Carroll, L. Carrique, P.N.M. Shah, W. James, M.L. Knight, J.A. Tree, K.R. Buttigieg, N. Coombes, M.J. Meredith, A.S. Azman, N.G. Reich, J. Lessler, The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. *Ann. Intern. Med.* **172**, 577–582 (2020). https://doi.org/10.7326/M20-0504

37. D.K.W. Chu, Y. Pan, S.M.S. Cheng, K.P.Y. Hui, P. Krishnan, Y. Wang, D.Y.M. Ng, C.K.C. Wan, P. Yang, Q. Wang, M. Peiris, L.L.M. Poon, Molecular diagnosis of a novel coronavirus (2019-nCoV) causing an outbreak of pneumonia. *Clin. Chem.* **66**, 549–555 (2020). https://doi.org/10.1093/clinchem/hva029

38. S. Itravani, Nano- and biosensors for the detection of SARS-CoV-2: challenges and opportunities. *Mater. Adv.* **1**, 3092–3103 (2020). https://doi.org/10.1039/D0MA00702A

39. W. Feng, A.M. Newbigeing, C. Le, B. Pang, H. Peng, Y. Cao, J. Wu, G. Abbas, J. Song, D.-B. Wang, M. Cui, J. Tao, D.L. Tyrrell, X.-E. Zhang, H. Zhang, X.C. Le, Molecular diagnosis of COVID-19: challenges and research needs. *Anal. Chem.* **92**, 10196–10209 (2020). https://doi.org/10.1021/acs.analchem.0c02060

40. Z. Li, Y. Yi, X. Luo, X. Niong, Y. Liu, S. Li, R. Sun, Y. Wang, B. Hu, W. Chen, Y. Zhang, J. Wang, B. Huang, Y. Lin, J. Yang, W. Cai, X. Wang, J. Cheng, Z. Chen, K. Sun, W. Pan, Z. Zhan, L. Chen, F. Ye, Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis. *J. Med. Virol.* **92**, 1518–1524 (2020). https://doi.org/10.1002/jmv.25727

41. J.F.-W. Chan, C.C.-Y. Yip, K.K.-W. To, T.H.-C. Tang, S.C.-Y. Wong, K.-H. Leung, A.Y.-F. Fung, A.C.-K. Ng, Z. Zou, H.-W. Tsai, G.K.-Y. Choi, A.R. Tam, V.C.-C. Cheng, K.-H. Chan, O.T.-Y. Tsang, K.-Y. Yuen, Improved molecular diagnosis of COVID-19 by the novel, highly sensitive and specific COVID-19-RdRp/CEA real-time reverse transcription-PCR assay validated *In Vitro* and with clinical specimens. *J. Clin. Microbiol.* **58**, e00310–e00320 (2020). https://doi.org/10.1128/JCM.00310-20

42. W. Liu, L. Liu, G. Kou, Y. Zheng, Y. Ding, W. Ni, Q. Wang, L. Zhu, Y. Zhang, J. Wang, B. Huang, Y. Lin, J. Yang, W. Pan, Z. Zhan, L. Chen, B. Huang, Y. Zhang, J. Wang, B. Huang, Y. Lin, J. Yang, W. Cai, X. Wang, J. Cheng, Z. Chen, K. Sun, W. Pan, Z. Zhan, L. Chen, F. Ye, Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis. *J. Med. Virol.* **92**, 1518–1524 (2020). https://doi.org/10.1002/jmv.25727
emergent mater. (2021) 4:231–247

Proc. Natl. Acad. Sci. U. S. A. 101, 2356–2541 (2004). https://doi.org/10.1073/pnas.030714101

51. M.H. Kubala, O. Kovalt, K. Alexandrov, B.M. Collins, Structural and thermodynamic analysis of the GFP-GFP-nanobody complex. Protein Sci. 19, 2389–2401 (2010). https://doi.org/10.1002/pro.519

52. A.L. Main, T.S. Harvey, M. Baron, J. Boyd, I.D. Campbell, The three-dimensional structure of the tenth type III module of fibronectin: an insight into RGD-mediated interactions. Cell 71, 671–678 (1992). https://doi.org/10.1016/0092-8674(92)90600-H

53. G.P. Smith, V.A. Petrenko, Phage display. Chem. Rev. 97, 391–410 (1997). https://doi.org/10.1021/cr960065d

54. P. Linsakul, Q. Peng, Y. Wu, M.E. Allen, J. Liang, A. G. Remacle, T. Lopez, X. Ge, B.K. Kay, H. Zhao, A.Y. Strongin, X.-L. Yang, S. Lu, Y. Wang. Directed evolution to engineer monobody for FRET biosensor assembly and imaging at live-cell surface. Cell Chemical Biology 25, 370–379.e4 (2018). https://doi.org/10.1016/j.chembiol.2018.01.002

55. S. Harmansa, M. Affolter, Protein binders and their applications in developmental biology. Development 145, dev148874 (2018). https://doi.org/10.1242/dev.148874

56. G.P. Smith, filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science 228, 1315–1317 (1985). https://doi.org/10.1126/science.4001944

57. L. Zhang, B. Zheng, X. Gao, L. Zhang, H. Pan, Y. Qiao, G. Suo, F. Zhu. Development of patient-derived human monoclonal antibodies against nucleocapsid protein of severe acute respiratory syndrome coronavirus 2 for coronavirus disease 2019 diagnosis. Front. Immunol. 11, 595970 (2020). https://doi.org/10.3389/fimmu.2020.595970

58. B. Ju, Q. Zhang, J. Ge, R. Wang, J. Sun, X. Ge, J. Yu, S. Shan, B. Zhou, S. Song, X. Tang, J. Yu, J. Lan, J. Yuan, H. Wang, J. Zhao, S. Zhang, Y. Wang, X. Shi, L. Liu, J. Zhao, X. Wang, Z. Zhang, L. Zhang. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature 584, 115–119 (2020). https://doi.org/10.1038/s41586-020-2380-z

59. T. Noy-Porat, E. Makdasi, R. Alcalay, A. Mechaly, Y. Levy, A. Bercovic-Kinori, A. Zaunma, H. Tamir, Y. Yahalom-Ronen, M.A. Israeli, E. Epstein, H. Achdout, S. Melamed, T. Chittani, S. Weiss, E. Peretz, O. Rosen, N. Paran, S. Yitzhaki, S.C. Shapira, T. Issacly, O. Mazor, R. Rosenfeld, A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes. Nat. Commun. 11, 4303 (2020). https://doi.org/10.1038/s41467-020-18159-4

60. C. Wang, W. Li, D. Drabek, N.M.A. Okba, R. van Haperen, A.D.M.E. Osterhaus, F.J.M. van Kuppeveld, B.L. Haagmans, F. Grosveld, B.-J. Bosch, A human monoclonal antibody blocking SARS-CoV-2 infection. Nat. Commun. 11, 2251 (2020). https://doi.org/10.1038/s41467-020-16256-y

61. X. Tian, C. Li, A. Huang, S. Xia, S. Lu, Z. Shi, L. Lu, S. Jiang, Z. Yang, Y. Wu, T. Ying. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. Emerg. Microbes Infect. 9, 382–385 (2020). https://doi.org/10.1080/22221717.2020.1729069

62. Y. Xiang, S. Nambulli, Z. Xiao, H. Liu, Z. Sang, W.P. Duprex, D. Schneidman-Duhovny, D. C. Hockett, S. Muddima, A. Guihot, C.-E. Luyt, J. Mayaux, A. Beurton, S. Fourati, T. Brueil, O. Schwartz, J.-M. Lacorte, H. Yssel, C. Parizot, K. Dorgham, P. Charneau, Z. Amourea, G. Gorochov, IgA dominates the early neutralizing antibody response to SARS-CoV-2. Sci. Transl. Med. 13, eabd2223 (2020). https://doi.org/10.1126/scitranslmed.aabd2223

63. V.M. Corman, O. Landt, M. Kaiser, R. Molenkamp, A. Meijer, D.K. Chu, T. Bleeker, B. Brünink, J. Schneider, M.L. Schmidt, D.G. Mulders, B.L. Haagmans, B. van de Veer, S. van den Brink, W. Wijsman, G. Goderski, J.-L. Romette, J. Ellis, M. Zambon, M. Peiris, H. Goossens, C. Reusken, M.P. Koopmans, C. Drosten, Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill. 25, 2000045 (2020). https://doi.org/10.2807/1560-7917.ES.2020.25.3.2000045

64. In Vitro Diagnostics EUAs. Food and Drug Administration [cited Access January 18, 2021]; Available from: https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/vitro-diagnostics-euas
87. Zainuddin, A.A., A.N. Nordin, M.A.M. Asri, R. Ab Rahim, C. L.J. Carter, L.V. Garner, J.W. Smoot, Y. Li, Q. Zhou, C.J. T. Notomi, H. Okayama, H. Masubuchi, T. Yonekawa, K. T. Ai, Z. Yang, H. Hou, C. Zhan, C. Chen, W. Lv, Q. Tao, Z. Sun, S. Mavrikou, G. Moschopoulou, V. Tsekouras, S. Kintzios, 2020. Development of ultrasensitive, multiplexed and rapid point-of-care dengue detection arrays: towards ultrasensitive, multiplexed and rapid point-of-care dengue detection arrays. 

88. T. Notomi, H. Okayama, H. Masubuchi, T. Yonekawa, K. T. Ai, Z. Yang, H. Hou, C. Zhan, C. Chen, W. Lv, Q. Tao, Z. Sun, S. Mavrikou, G. Moschopoulou, V. Tsekouras, S. Kintzios, 2020. Development of ultrasensitive, multiplexed and rapid point-of-care dengue detection arrays: towards ultrasensitive, multiplexed and rapid point-of-care dengue detection arrays. 

89. S. Menon, M.R. Mathew, S. Sam, K. Keerthi, K.G. Kumar, 2020. Development of a portable, ultra-rapid and ultra-sensitive cell-based biosensor for the direct detection of the SARS-CoV-2 S1 spike protein antigen. 

90. A. Yakoh, U. Pimpitak, S. Rengpipat, N. Hirankarn, O. Chailapakul, S. Chaiyo, Paper-based electrochemical biosensor for diagnosing COVID-19: detection of SARS-CoV-2 antibodies and antigen. 

91. R. Singh, S. Hong, J. Jang, Label-free detection of influenza viruses using a reduced graphene oxide-based electrochemical sensing system. 

92. H. Zhang, B.L. Miller, Immunosensor-based label-free and multiplex detection of influenza viruses: state of the art. 

93. A. Parihar, P. Ranjan, S.K. Sanghi, A.K. Srivastava, R. Khan, Point-of-care biosensor-based diagnosis of COVID-19 holds promise to combat current and future pandemics. 

94. A. Yakoh, U. Pimpitak, S. Rengpipat, N. Hirankarn, O. Chailapakul, S. Chaiyo, Paper-based electrochemical biosensor for diagnosing COVID-19: detection of SARS-CoV-2 antibodies and antigen. 

95. A. Parihar, P. Ranjan, S.K. Sanghi, A.K. Srivastava, R. Khan, Point-of-care biosensor-based diagnosis of COVID-19 holds promise to combat current and future pandemics. 

96. Mahapatra, S., A. Baranwal, B. Purohit, S. Roy, K.S. Mahto, and P. Chandra, Advanced biosensing methodologies for ultrasensitive detection of human coronaviruses, in Diagnostics for COVID-19 and other coronaviruses. 2020, Springer. p. 19-36. 

97. A. Parihar, P. Ranjan, S.K. Sanghi, A.K. Srivastava, R. Khan, Point-of-care biosensor-based diagnosis of COVID-19 holds promise to combat current and future pandemics. 

98. Mahapatra, S., A. Baranwal, B. Purohit, S. Roy, K.S. Mahto, and P. Chandra, Advanced biosensing methodologies for ultrasensitive detection of human coronaviruses, in Diagnostics for COVID-19 and other coronaviruses. 2020, Springer. p. 19-36. 

99. H. Zhang, B.L. Miller, Immunosensor-based label-free and multiplex detection of influenza viruses: state of the art. 

100. A. Parihar, P. Ranjan, S.K. Sanghi, A.K. Srivastava, R. Khan, Point-of-care biosensor-based diagnosis of COVID-19 holds promise to combat current and future pandemics. 

101. P. Chandra, Miniaturized label-free smartphone assisted electrochemical sensing approach for personalized COVID-19 diagnosis. 

102. A. Parihar, P. Ranjan, S.K. Sanghi, A.K. Srivastava, R. Khan, Point-of-care biosensor-based diagnosis of COVID-19 holds promise to combat current and future pandemics. 

103. A. Parihar, P. Ranjan, S.K. Sanghi, A.K. Srivastava, R. Khan, Point-of-care biosensor-based diagnosis of COVID-19 holds promise to combat current and future pandemics. 

104. A. Parihar, P. Ranjan, S.K. Sanghi, A.K. Srivastava, R. Khan, Point-of-care biosensor-based diagnosis of COVID-19 holds promise to combat current and future pandemics.
105. Q.Y. Siew, E.L. Pang, H.-S. Loh, M.T.T. Tan, Highly sensitive and specific graphene/TiO2 impedimetric immunosensor based on plant-derived tetravalent envelope glycoprotein domain III (EDIII) probe antigen for dengue diagnosis. *Biosens. Bioelectron.* **176**, 112895 (2020). https://doi.org/10.1016/j.bios.2020.112895

106. S. Hideshima, H. Hayashi, H. Hinou, S. Nambuya, S. Kuroiwa, T. Nakanishi, T. Momma, S.-I. Nishimura, Y. Sakoda, T. Osaka, Glycan-immobilized dual-channel field effect transistor biosensor for the rapid identification of pandemic influenza virus particles. *Sci. Rep.* **9**, 11616 (2019). https://doi.org/10.1038/s41598-019-48076-6

107. C. Wu, X. Chen, Y. Cai, J.A. Xia, X. Zhou, S. Xu, H. Huang, L. Zhang, X. Zhou, C. Du, Y. Zhang, J. Song, S. Wang, Y. Chao, Z. Yang, J. Xu, X. Zhou, D. Chen, W. Xiong, L. Xu, F. Zhou, J. Jiang, C. Bai, J. Zheng, Y. Song, Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. *JAMA Intern. Med.* **180**, 934–943 (2020). https://doi.org/10.1001/jama.2020.0994

108. S. Chen, Y. Liu, J. Chen, Heterogeneous electron transfer at nanoscopic electrodes: importance of electronic structures and electric double layers. *Chem. Soc. Rev.* **43**, 5372–5386 (2014). https://doi.org/10.1039/C4CS00087K

109. H. Beitollahi, F. Movahedifar, S. Tajik, S. Jahani, A review on the effects of introducing CNTs in the modification process of electrochemical. Sensors **31**, 1195–1203 (2019). https://doi.org/10.1002/elcn.201800370

110. A.A. Lahcen, S. Rauf, T. Beduk, C. Durmus, A. Aljedaibi, S. Zhang, R. Geryak, J. Geldmeier, S. Kim, V.V. Tsukruk, Synthesis, assembly, and applications of hybrid nanostructures for biosensing. *Chem. Rev.* **117**, 12942–13038 (2017). https://doi.org/10.1021/acs.chemrev.7b00088

111. H.J. Kim, M.H. Lee, L. Muthiac, J. Vicens, J.S. Kim, Host–guest sensing by calixarenes on the surfaces. *Chem. Soc. Rev.* **41**, 1173–1190 (2012). https://doi.org/10.1039/C1CS15169J

112. M. Pastucha, Z. Farka, K. Lacina, Z. Mikušová, P. Skládal, Magnetic nanoparticles for smart electrochemical immunosassays: a review on recent developments. *Microchem. Acta* **186**, 312 (2019). https://doi.org/10.1007/s00604-019-3410-0

113. A. Walcarius, Silica-based electrochemical sensors and biosensors: recent trends. *Cur. Opin. Electrochem.* **10**, 88–97 (2018). https://doi.org/10.1016/j.coelcoc.2018.03.017

114. M.A. Farzin, H. Abdoos, A critical review on quantum dots: from synthesis toward applications in electrochemical biosensors for determination of disease-related biomolecules. *Talanta* **224**, 121828 (2021). https://doi.org/10.1016/j.talanta.2020.121828

115. S. Zhang, R. Geryak, J. Geldmeier, S. Kim, V.V. Tsukruk, Synthesis, assembly, and applications of hybrid nanostructures for biosensing. *Chem. Rev.* **117**, 12942–13038 (2017). https://doi.org/10.1021/acs.chemrev.7b00088

116. M. Santhanam, I. Algov, L. Alfönta, DNA/RNA electrochemical biosensing devices a future replacement of PCR methods for a fast epidemic containment. *Sensors* **20** (2020). https://doi.org/10.3390/s20164648

117. S.A. Lim, M.U. Ahmed, Electrochemical immunosensors and their recent nanomaterial-based signal amplification strategies: a review. *RSC Adv.* **6**, 24995–25014 (2016). https://doi.org/10.1039/C6RA0333H

118. C. Yang, M.E. Denno, P. Pyakurel, B.J. Venton, Recent trends in carbon nanomaterial-based electrochemical sensors for biomolecules: a review. *Anal. Chim. Acta* **887**, 17–37 (2015). https://doi.org/10.1016/j.aca.2015.05.049

119. P.A. Rasheed, N. Sandhyarani, Electrochemical DNA sensors based on the use of gold nanoparticles: a review on recent developments. *Microchem. Acta* **184**, 981–1000 (2017). https://doi.org/10.1007/s00604-017-2143-1

120. M. Alagiri, P. Rameshkumar, A. Pandikumar, Gold nanorod-based electrochemical sensing of small biomolecules: a review. *Microchim. Acta* **184**, 3069–3092 (2017). https://doi.org/10.1007/s00604-017-2418-6

121. L. Jiang, J. Han, F. Li, J. Gao, Y. Li, Y. Dong, Q. Wei, A sandwich-type electrochemical immunosensor based on multiple signal amplification for α-fetoprotein labeled by platinum hybrid multiwalled carbon nanotubes adhered copper oxide. *Electrochim. Acta* **160**, 7–14 (2015). https://doi.org/10.1016/j.electacta.2015.02.050

122. M. Asif, M. Ajmal, G. Ashraf, N. Muhammad, A. Aziz, T. Iftikhar, J. Wang, H. Liu, The role of biosensors in coronavirus disease-2019 outbreak. *Cur. Opin. Electrochem.* **23**, 174–184 (2020). https://doi.org/10.1016/j.coelcoc.2020.08.011

123. G. Qiu, Z. Gai, Y. Tao, J. Schmitt, G.A. Kullak-Ublick, J. Wang, Dual-functional plasmonic photothermal biosensors for highly accurate severe acute respiratory syndrome coronavirus 2 detection. *ACS Nano* **14**, 5268–5277 (2020). https://doi.org/10.1021/acsnano.0c02439